HTG Molecular Diagnostics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 21.59 million compared to USD 17.15 million a year ago. Basic loss per share from continuing operations was USD 24.28 compared to USD 29.66 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | +66.67% | 0.00% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-11.49% | 19.08B | |
-46.21% | 2.65B | |
+18.15% | 1.87B | |
-3.12% | 1.61B | |
+22.66% | 1.21B | |
-10.69% | 1.02B | |
-20.89% | 905M | |
-5.89% | 716M | |
-18.10% | 682M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022